Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Other Non-Current Assets (2016 - 2025)

Cytokinetics (CYTK) has disclosed Other Non-Current Assets for 16 consecutive years, with $17.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets changed N/A to $17.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $17.3 million, a N/A change, with the full-year FY2025 number at $17.3 million, changed N/A from a year prior.
  • Other Non-Current Assets was $17.3 million for Q4 2025 at Cytokinetics, up from $14.6 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $17.3 million in Q4 2025 to a low of $6.4 million in Q1 2021.
  • A 5-year average of $9.1 million and a median of $7.8 million in 2024 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: fell 17.49% in 2023, then surged 89.52% in 2025.
  • Cytokinetics' Other Non-Current Assets stood at $7.2 million in 2021, then soared by 34.82% to $9.7 million in 2022, then fell by 17.49% to $8.0 million in 2023, then decreased by 3.96% to $7.7 million in 2024, then skyrocketed by 125.82% to $17.3 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Other Non-Current Assets are $17.3 million (Q4 2025), $14.6 million (Q2 2025), and $12.7 million (Q1 2025).